Official recall notice

FDA DrugClass IINotable

FDA Recall: MYXREDLIN, Insulin Human in 0.9% Sodium Chloride Injection, 100 units/100 mL (1 unit/mL), Rx only, B

Recall date
2026-09-09
Category
Drug
FDA class
Class II

Why it was recalled

Hazard

CGMP Deviations

Product description

CGMP Deviations

Affected products

Lot # NC188630, NC188708, NC188791, NC188845, NC188876, NC188968, Exp Date: 12/31/2027; Lot # NC193719, NC193849, Exp Date: 04/30/2028; Lot # NC194051, NC194105, Exp Date: 05/31/2028; Lot # NC195171, Exp Date: 06/30/2028.

Verify with the official notice →
Share:

Related Recalls

2026-09-09 · FDA_DRUG
FDA Recall: Clindamycin Injection USP in 5% Dextrose, 600 mg per 50 mL (12 mg/mL) in GALAXY 50 mL Single Dose Co
Baxter Healthcare Corporation
2026-09-09 · FDA_DRUG
FDA Recall: Vasopressin, in 0.9% Sodium Chloride Injection, 40 units per 100 mL (0.4 units/mL), 100mL Single-Dos
Baxter Healthcare Corporation
2026-09-09 · FDA_DRUG
FDA Recall: Daptomycin, in 0.9% Sodium Chloride Injection, 1,000 mg per 100 mL (10 mg/mL), 1,000 mg total, in 10
Baxter Healthcare Corporation
2026-09-09 · FDA_DRUG
FDA Recall: Vancomycin Injection, USP in 5% Dextrose, 1 g per 200mL (5 mg/mL), in GALAXY Single-Dose Container,
Baxter Healthcare Corporation